The European Consortium for Communicating Stem Cell Research (EuroStemCell) unites 33 partner institutions, that collectively represent >400 stem cell research groupings across Europe. Our common goal is to provide trusted high quality information on stem cells accessible to citizens and stakeholders across Europe, through support and further development of the multi-lingual European Stem Cell Information Portal www.eurostemcell.org. To achieve our aims, EuroStemCell will adopt the highly structured system for coordinated information management established by the FP7 Coordination and Support Action (CSA) also called EuroStemCell. From this, we will implement an ambitious programme of online and direct stakeholder engagement with stem cell research and regenerative medicine, aimed at European citizens at all educational levels. This will include provision of resources tailored specifically for decision-making on stem cell-related questions and an extensive programme of dissemination and capacity building in science communications and public engagement. The proposed work centres on an information hub team, which will link to all project partners and to stakeholders in the stem cell and regenerative medicine arenas and wider society, working with these groupings to implement the project. All outputs will be delivered in 6 European languages, to ensure broad accessibility, and will be rigorously evaluated against measurable objectives throughout the project duration. The proposed consortium comprises leading stem cell labs across Europe, including new member states, together with experts in ethical and societal concerns and evaluating clinical outcomes. It thus provides unparalleled European expertise across the fields of stem cell biology and regenerative medicine and is uniquely placed to maintain and further develop www.eurostemcell.org as a world-leading stem cell information resource, thus meeting the challenge outlined in Topic HOA-6-2014.

The European Consortium for Communicating Gene and Cell Therapy Information (EuroGCT) unites 49 partner organisations and institutions across Europe, including the major European advanced therapies learned societies, with the common goal of providing reliable and accessible information related to cell and gene therapy development to European stakeholders. EuroGCT has two major objectives: • To provide patients, people affected by conditions, healthcare professionals and citizens with accurate scientific, legal, ethical and societal information and with engagement opportunities, and thus to support better informed decision-making related to cell and gene-based therapies. • To facilitate better decision-making at key points in development of new therapies and thus enable improved product development, by providing the research community and regulatory and healthcare authorities with an information source on the practical steps needed for cell and gene therapy development. To achieve our aims, EuroGCT will adopt a highly structured system for coordinated management of information related to cell and gene therapy development and, from this, will implement an ambitious programme of online and direct stakeholder information provision and engagement. All outputs will be delivered in 7 European languages, to ensure broad accessibility, and will be rigorously evaluated against measurable objectives throughout the project duration. The proposed consortium comprises leading cell and gene therapy-related organisations and basic and clinical research labs across Europe, including new member states; together with experts in product development, ethical, legal and societal issues, and in evaluating clinical outcomes; patient representatives; and science communicators. It thus is uniquely placed to develop a world-leading cell and gene therapy information resource and to meet the challenge outlined in Topic SC1-HCO-19-2020.